Cost-Effectiveness of Pioglitazone in Type 2 Diabetes Patients With a History of Macrovascular Disease: A German Perspective
Cost Effectiveness and Resource Allocation - United Kingdom
doi 10.1186/1478-7547-7-9
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2009
Authors
Publisher
Springer Science and Business Media LLC